30 closest matches · ranked by relevance
Advanced Malignant Solid Neoplasm · Cholangiocarcinoma · Metastatic Malignant Solid Neoplasm
Primary: Overall Response Rate (ORR) — 13.3 percentage of participants
Hepatocellular Carcinoma (HCC) · Solid Malignancies
Primary: Number of Participants With Dose-limiting Toxicity (DLT): Phase I Only — 10.0; 0; 0; 4.3 Percentage of participants
Recurrent Glioblastoma or Other Glioma Subtypes
Primary: Progression Free Survival — 1.7 months
Advanced Lymphoma · Advanced Malignant Solid Neoplasm · Hematopoietic and Lymphoid Cell Neoplasm
Primary: Overall Response Rate (ORR) — 8 percentage of participants
Advanced Solid Tumor
Primary: Broad Panel and Pediatric Cohorts: Objective Response Rate (ORR) Based on Response Assessment in Neuro-Oncology (RANO) as Assessed by Independent Review Committee (IRC)…
Intrahepatic Cholangiocarcinoma · Combined Hepatocellular and Cholangiocarcinoma
Primary: Substudy 1: Objective Response Rate (ORR) — 22.3 Percentage of participants
Malignant Hepatobiliary Neoplasm
Primary: Clinical Benefit Rate (Percentage), Which Includes Confirmed Tumor Response (Complete Response [CR] or Partial Response [PR]) or Stable Disease (SD) — 45.5 percentage of…
Metastatic Breast Cancer
Primary: Number of Participants With Dose Limiting Toxicities (DLT) in the First Cycle for the Determination of the Maximum Tolerated Dose (MTD) — 0; 0; 2 participants
Neoplasms
Primary: Maximum Tolerated Dose (MTD), Defined as Maximum Dose at Which the Incidence of Dose Limiting Toxicities (DLTs) During Cycle 1 is Below 20% — 800 mg BID
MPN (Myeloproliferative Neoplasms)
Primary: Percentage of Participants Who Achieved Complete Response (CR) as Determined by Investigator Assessment According to the Response Criteria for Myeloid/Lymphoid Neoplasms…
FGFR1 Gene Amplification · FGFR1 Gene Mutation · FGFR2 Gene Amplification
Primary: Objective Response Rate (Confirmed and Unconfirmed, Complete and Partial) — 7 percentage of participants
Neoplasms
Primary: Number of Participants With Non-serious Adverse Events (AEs) and Serious AEs (SAEs) — 3; 3; 14; 3 Participants
Tumors
Primary: Part 1: Number of Participants With Dose-limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Solid Tumor
Primary: Number of Patients With Drug-related Treatment-emergent Adverse Events (TEAEs) — 3; 1; 1; 11 Participants
FGFR Inhibition, Pharmacokinetics, Biomarkers · ER+ Breast Cancer
Primary: Safety and Tolerability in Terms of Number of Patients With Adverse Events (Serious and Non-serious) — 5; 5; 12; 9 Participants
Malignant Neoplasm
Primary: Overall Response, Defined as the Number of Patients Who Achieve Any Response According to Disease Type in the First 6 Courses of Treatment — 1; 0 Participants
Carcinoma, Transitional Cell
Primary: Objective Response Rate (ORR) - Central Assessment — 19.5; 21.6; 19.4; 23.8 percentage of participants — p==0.6991
Glioma
Primary: Number of Patients Who Had 6-month Progression-free Survival. — 3 Participants
UC (Urothelial Cancer)
Primary: Objective Response Rate (ORR) in Participants With FGFR3 Mutations or Fusions on a CD Regimen — 17.8 percentage of participants
Solid Tumors and Advanced Endometrial Cancer · Endometrial Cancer · Second-line Treatment
Primary: Progression Free Survival (PFS) Rate — 31.8; 29.0 Percentage of participants
Non-Small Cell Lung Cancer (NSCLC)
Primary: Objective Response Rate (ORR) in Cohort A — 33.3 percentage of participants
Non-Small Cell Lung Cancer
Primary: Objective Response Rate — 10.7; 15.0; 25.0; 0.0 percentage of participants — p=0.94
Cholangiocarcinoma · Urothelial Cancer · Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR Tumors
Primary: Phase 1: Dose Escalation-Maximum Tolerated Dose (MTD) — NA; 20 Milligrams
Carcinoma, Non-Small-Cell Lung
Primary: Objective Response Rate — 54.1; 40.5 Percentage of participants
Glioblastoma · Brain Tumor, Recurrent
Primary: Progression-free Survival (PFS) at Six Months (PFS6m) — 26; 4; 16; 1 Participants
Non-small Cell Lung Cancer (NSCLC)
Primary: Progression-Free Survival — 14 Participants
Urothelial Carcinoma
Primary: Number of Participants With Dose-limiting Toxicities(DLTs) — 1; 4 Participants
Carcinoma, Non-Small-Cell Lung
Primary: Percentage of Participants With Best Objective Response — 13.0 percentage of participants
Urothelial Carcinoma
Primary: Objective Response Rate (ORR) Based on RECIST 1.1 (Substudies 1,3,4 and 5) — 9.4; 0.0; 14.3; 0.0 Percentage of participants
Gastrointestinal Stromal Tumors
Primary: Disease Control Rate (DCR; OR + Stable Disease) — 13 Percentage of participants